Benzinga | Jun 30, 2021 11:17AM EDT

Alpine Immune Sciences Initiates Trial Collaboration With Merck

* Alpine Immune Sciences Inc (NASDAQ:ALPN) has entered into a clinical trial collaboration and supply agreement with Merck & Co Inc (NYSE:MRK).

* This collaboration will evaluate the safety and efficacy of Alpine's ALPN-202 in combination with Merck's Keytruda (pembrolizumab) in patients with advanced malignancies.

* Dubbed as NEON-2, the trial is currently enrolling.

* Price Action: ALPN shares are down 1.93% at $8.92 during the market session on the last check Wednesday.